Hafslund Nycomed (Norway) moves into nuclear medicine
This article was originally published in Clinica
Hafslund Nycomed (Norway) has added a new dimension to its Imaging Division through an investment in Diatech's (US) nuclear medicine imaging agents. The development and marketing agreement gives Nycomed a five-year option to an exclusive licence for Europe and the Middle East as well as an exclusive co-promotion agreement for the agents in the US. In return, Hafslund Nycomed will make a $10 million equity investment in Diatech and provide R&D support. Diatech will also receive additional payments and royalties.